Drugs / LEXIBULIN
LEXIBULIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00650949 | Nov 2009 → Jun 2011 | glioblastoma | Gilead Sciences | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT00664378 | Jan 2008 → Feb 2011 | refractory plasma cell neoplasm | Gilead Sciences | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEXIBULIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL552212 ↗ |
| Known as | CYT997 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00664378 ↗ |
| Known as | Lexibulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL552212 ↗ |
| Known as | Lexibuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL552212 ↗ |
| Modality | Small molecule | — CHEMBL552212 ↗ |
| Route | Intravenous | “24-hour intravenous infusion on Day 2 of a 21-day cycle” NCT00650949 ↗ |